National Center for Health Statistics (NCHS), ICD-10 Coordination and Maintenance (C&M) Committee Meeting, 40054-40055 [2021-15801]
Download as PDF
<![CDATA[
40054
Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondents
Form name
EDN data entry staff at state and local health
departments.
US Tuberculosis Follow-up Worksheet for
Newly-Arrived Persons with Overseas Tuberculosis Classifications.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–15793 Filed 7–23–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Center for Health Statistics
(NCHS), ICD–10 Coordination and
Maintenance (C&M) Committee
Meeting
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
The CDC, National Center for
Health Statistics (NCHS), Classifications
and Public Health Data Standards Staff,
announces the following meeting of the
ICD–10 Coordination and Maintenance
(C&M) Committee meeting. This
meeting is open to the public, limited
only by audio. Online Registration is not
required.
DATES: The meeting will be held on
September 14, 2021, from 9:00 a.m. to
5:00 p.m., EDT, and September 15,
2021, from 9:00 a.m. to 5:00 p.m., EDT.
ADDRESSES: This is a virtual meeting.
Information will be provided on each of
our respective web pages when it
becomes available. For CDC/NCHS
https://www.cdc.gov/nchs/icd/icd10cm_
maintenance.htm. For CMS https://
www.cms.gov/Medicare/Coding/
ICD9ProviderDiagnosticCodes/meetings.
FOR FURTHER INFORMATION CONTACT:
Traci Ramirez, Medical Systems
Specialist, CDC, 3311 Toledo Road,
Hyattsville, Maryland 20782;
Telephone: (301) 458–4454; Email:
TRamirez@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The ICD–10 Coordination
and Maintenance (C&M) Committee is a
public forum for the presentation of
proposed modifications to the
International Classification of Diseases,
jbell on DSKJLSW7X2PROD with NOTICES
VerDate Sep<11>2014
17:10 Jul 23, 2021
Jkt 253001
Tenth Revision, Clinical Modification
and ICD–10 Procedure Coding System.
Matters To Be Considered: The
tentative agenda will include
discussions on ICD–10–CM and ICD–
10–PCS topics listed below. Agenda
items are subject to change as priorities
dictate.
Please refer to the posted agenda for
updates one month prior to the meeting.
ICD–10–PCS Topics
Centers for Disease Control and
Prevention
SUMMARY:
Number of
respondents
1. Administration of fostamatinib(1), (2)
2. Administration of betibeglogene
autotemcel (beti-cel)(1)
3. Administration of RBX2660(1)
4. Pressure-controlled Intermittent
Coronary Sinus Occlusion
5. Measurement of Exhaled Nitric Oxide
(FeNo)
6. Histotripsy of Liver
7. Replacement of Meniscus with
Synthetic Substitute (1)
8. Section X Updates
9. Addenda and Key Updates
(1) Applicant intends to submit a New
Technology Add-on Payment (NTAP)
application for FY 2023.
(2) Request is for an April 1, 2022
implementation date.
Presentations for procedure code
requests are conducted by both the
requestor and CMS during the
Coordination & Maintenance Committee
meeting. Discussion from the requestor
generally focuses on the clinical issues
for the procedure or technology,
followed by the proposed coding
options from a CMS analyst. Topics
presented may also include requests for
new procedure codes that relate to a
new technology add-on payment
(NTAP) policy request.
CMS is continuing to modify the
approach for presenting the new
technology add-on payment (NTAP)
related ICD–10–PCS procedure code
requests that involve the administration
of a therapeutic agent. Consistent with
the requirements of section
1886(d)(5)(K)(iii) of the Social Security
Act, applicants submitted requests to
create a unique procedure code to
describe the administration of a
therapeutic agent, such as the option to
create a new code in Section X within
the ICD–10–PCS procedure code
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
1,548
Number of
responses per
respondent
3
Average
burden per
response
(in hours)
30/60
classification. CMS will initially only
display those meeting materials
associated with the NTAP related ICD–
10–PCS procedure code requests that
involve the administration of a
therapeutic agent on the CMS website in
early August 2021 at: https://
www.cms.gov/Medicare/Coding/ICD10/
C-and-M-Meeting-Materials.
The three NTAP related ICD–10–PCS
procedure code requests that involve the
administration of a therapeutic agent
are:
1. Administration of fostamatinib
2. Administration of betibeglogene
autotemcel (beti-cel)
3. Administration of RBX2660
These topics will not be presented
during the September 14–15, 2021
meeting. CMS will solicit public
comments regarding any clinical
questions or coding options included for
these three procedure code topics in
advance of the meeting continuing
through the end of the public comment
period. The deadline to submit
comments for topics being considered
for April 1, 2022 implementation is
October 15, 2021 and the deadline to
submit comments for topics being
considered for an October 1, 2022
implementation is November 15, 2021.
Members of the public should send any
questions or comments to the CMS
mailbox at: ICDProcedureCodeRequest@
cms.hhs.gov by the designated deadline
dates mentioned above.
CMS intends to post a question and
answer document in advance of the
meeting to address any clinical or
coding questions that members of the
public may have submitted. Following
the conclusion of the meeting, CMS will
post an updated question and answer
document to address any additional
clinical or coding questions that
members of the public may have
submitted during the meeting that CMS
was not able to address or that were
submitted after the meeting.
The NTAP related ICD–10–PCS
procedure code requests that do not
involve the administration of a
therapeutic agent and all non-NTAP
related procedure code requests will
continue to be presented during the
virtual meeting on September 14, 2021
E:\FR\FM\26JYN1.SGM
26JYN1
Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices
consistent with the standard meeting
process.
CMS will make all meeting materials
and related documents available at:
https://www.cms.gov/Medicare/Coding/
ICD10/C-and-M-Meeting-Materials. Any
inquiries related to the procedure code
topics scheduled for the September 14,
2021 ICD–10 Coordination and
Maintenance Committee meeting that
are under consideration for April 1,
2022 or October 1, 2022 implementation
should be sent to the CMS mailbox at:
ICDProcedureCodeRequest@
cms.hhs.gov.
ICD–10–CM Topics
1. Apnea of Newborn and Related Issues
2. Atrial Septal Defect
3. Craniosynostosis
4. Dementia
5. Encounter for follow-up examination
after completed treatment for
malignant neoplasm
6. Endometriosis
7. Intracranial Injury with Unknown
LOC
8. Long-term (current) drug therapy
9. Primary Blast Injury
10. Problems Related to Upbringing
11. Short Stature Due to Endocrine
Disorder
12. Addenda
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–15801 Filed 7–23–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
jbell on DSKJLSW7X2PROD with NOTICES
[60Day–21–1046; Docket No. CDC–2021–
0074]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
VerDate Sep<11>2014
17:10 Jul 23, 2021
Jkt 253001
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled National Breast and Cervical
Cancer Early Detection Program
(NBCCEDP) Monitoring Activities.
Proposed study is designed to collect
information about implementation,
including delivery of screening and
follow-up clinical services, and
outcomes of the NBCCEDP.
DATES: CDC must receive written
comments on or before September 24,
2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2021–
0074 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
40055
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
National Breast and Cervical Cancer
Early Detection Program (NBCCEDP)
Monitoring Activities—(OMB Control
No. 0920–1046, Exp. 11/30/2021)—
Revision—National Center for Chronic
Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
CDC is requesting a Revision of the
information collection with the OMB
Control Number 0920–1046, titled
‘‘National Breast and Cervical Cancer
Early Detection Program (NBCCEDP)
Monitoring Activities.’’ In the previous
OMB approval period, information
collection consisted of an annual
NBCCEDP survey and clinic-level data
collection. In the next OMB approval
period, information collection will
consist of a revised NBCCEDP survey,
revised clinic-level data collection, new
quarterly program update, new service
delivery projection worksheet, and the
addition of previously approved
minimum data elements (MDEs; OMB
Control No. 0920–0571, Exp. 11/30/
2021) to increase efficiency. The
number of respondents will remain the
same and the total estimated annualized
burden will increase from 683 to 1,216.
Breast and cervical cancers are
prevalent among U.S. women. In 2017,
the U.S. experienced 250,520 new cases
and 42,000 deaths as a result of breast
E:\FR\FM\26JYN1.SGM
26JYN1
]]>Agencies
[Federal Register Volume 86, Number 140 (Monday, July 26, 2021)]
[Notices]
[Pages 40054-40055]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-15801]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Health Statistics (NCHS), ICD-10 Coordination
and Maintenance (C&M) Committee Meeting
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The CDC, National Center for Health Statistics (NCHS),
Classifications and Public Health Data Standards Staff, announces the
following meeting of the ICD-10 Coordination and Maintenance (C&M)
Committee meeting. This meeting is open to the public, limited only by
audio. Online Registration is not required.
DATES: The meeting will be held on September 14, 2021, from 9:00 a.m.
to 5:00 p.m., EDT, and September 15, 2021, from 9:00 a.m. to 5:00 p.m.,
EDT.
ADDRESSES: This is a virtual meeting. Information will be provided on
each of our respective web pages when it becomes available. For CDC/
NCHS https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm. For CMS
https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.
FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Systems
Specialist, CDC, 3311 Toledo Road, Hyattsville, Maryland 20782;
Telephone: (301) 458-4454; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is
a public forum for the presentation of proposed modifications to the
International Classification of Diseases, Tenth Revision, Clinical
Modification and ICD-10 Procedure Coding System.
Matters To Be Considered: The tentative agenda will include
discussions on ICD-10-CM and ICD-10-PCS topics listed below. Agenda
items are subject to change as priorities dictate.
Please refer to the posted agenda for updates one month prior to
the meeting.
ICD-10-PCS Topics
1. Administration of fostamatinib(1), (2)
2. Administration of betibeglogene autotemcel (beti-cel)(1)
3. Administration of RBX2660(1)
4. Pressure-controlled Intermittent Coronary Sinus Occlusion
5. Measurement of Exhaled Nitric Oxide (FeNo)
6. Histotripsy of Liver
7. Replacement of Meniscus with Synthetic Substitute (1)
8. Section X Updates
9. Addenda and Key Updates
(1) Applicant intends to submit a New Technology Add-on Payment
(NTAP) application for FY 2023.
(2) Request is for an April 1, 2022 implementation date.
Presentations for procedure code requests are conducted by both the
requestor and CMS during the Coordination & Maintenance Committee
meeting. Discussion from the requestor generally focuses on the
clinical issues for the procedure or technology, followed by the
proposed coding options from a CMS analyst. Topics presented may also
include requests for new procedure codes that relate to a new
technology add-on payment (NTAP) policy request.
CMS is continuing to modify the approach for presenting the new
technology add-on payment (NTAP) related ICD-10-PCS procedure code
requests that involve the administration of a therapeutic agent.
Consistent with the requirements of section 1886(d)(5)(K)(iii) of the
Social Security Act, applicants submitted requests to create a unique
procedure code to describe the administration of a therapeutic agent,
such as the option to create a new code in Section X within the ICD-10-
PCS procedure code classification. CMS will initially only display
those meeting materials associated with the NTAP related ICD-10-PCS
procedure code requests that involve the administration of a
therapeutic agent on the CMS website in early August 2021 at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.
The three NTAP related ICD-10-PCS procedure code requests that
involve the administration of a therapeutic agent are:
1. Administration of fostamatinib
2. Administration of betibeglogene autotemcel (beti-cel)
3. Administration of RBX2660
These topics will not be presented during the September 14-15, 2021
meeting. CMS will solicit public comments regarding any clinical
questions or coding options included for these three procedure code
topics in advance of the meeting continuing through the end of the
public comment period. The deadline to submit comments for topics being
considered for April 1, 2022 implementation is October 15, 2021 and the
deadline to submit comments for topics being considered for an October
1, 2022 implementation is November 15, 2021. Members of the public
should send any questions or comments to the CMS mailbox at:
[email protected] by the designated deadline dates
mentioned above.
CMS intends to post a question and answer document in advance of
the meeting to address any clinical or coding questions that members of
the public may have submitted. Following the conclusion of the meeting,
CMS will post an updated question and answer document to address any
additional clinical or coding questions that members of the public may
have submitted during the meeting that CMS was not able to address or
that were submitted after the meeting.
The NTAP related ICD-10-PCS procedure code requests that do not
involve the administration of a therapeutic agent and all non-NTAP
related procedure code requests will continue to be presented during
the virtual meeting on September 14, 2021
[[Page 40055]]
consistent with the standard meeting process.
CMS will make all meeting materials and related documents available
at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. Any inquiries related to the procedure code topics scheduled
for the September 14, 2021 ICD-10 Coordination and Maintenance
Committee meeting that are under consideration for April 1, 2022 or
October 1, 2022 implementation should be sent to the CMS mailbox at:
[email protected].
ICD-10-CM Topics
1. Apnea of Newborn and Related Issues
2. Atrial Septal Defect
3. Craniosynostosis
4. Dementia
5. Encounter for follow-up examination after completed treatment for
malignant neoplasm
6. Endometriosis
7. Intracranial Injury with Unknown LOC
8. Long-term (current) drug therapy
9. Primary Blast Injury
10. Problems Related to Upbringing
11. Short Stature Due to Endocrine Disorder
12. Addenda
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-15801 Filed 7-23-21; 8:45 am]
BILLING CODE 4163-18-P
